Trade Mark Attorney expenses treated as revenue, clinical trial deduction limited to approved R&D labs

The ITAT upheld the CIT(A) decision to treat expenses paid to Trade Mark Attorneys as revenue expenditure, rejecting the Revenue's appeal for capital treatment. Regarding weighted deduction u/s 35(2AB)(1) for clinical trials, the ITAT reversed the CIT(A) order, disallowing the deduction for expenses incurred outside approved R&D labs. The ITAT held that the deduction is only available for in-house research and development facilities approved by the prescribed authority, based on legal interpretation. The Revenue's appeal was partially upheld on this issue.

---

---

ISSUES PRESENTED AND CONSIDERED

1. Whether professional fees and reimbursement of expenses paid to trademark attorneys for registration of product trademarks in foreign countries are revenue expenditures deductible as business expenses or capital expenditures attracting capitalization and depreciation.

2. Whether weighted deduction under section 35(2AB)(1) is allowable for expenditure on clinical drug trials incurred outside the prescribed/approved in-house research and development facilities.

ISSUE-WISE DETAILED ANALYSIS

Issue 1 - Characterisation of expenditure on foreign trademark registration (revenue v. capital)

Legal framework: Payments for registration of trademarks may be treated as either revenue expenditure (business expense) or capital expenditure (creation/acquisition of an asset) depending on whether the payment confers an enduring benefit or creates/augments an asset or new source of income.

Precedent treatment: The Tribunal in earlier assessment years allowed similar professional fees as revenue expenditure. The Supreme Court decisions in Finlay Mills and Empire Jute were cited by the assessee to support revenue treatment; Finlay Mills was relied upon for the proposition that registration of a trade mark is not necessarily a capital expenditure because registration merely simplifies proof of title and is not, in that sense, an asset conferring an enduring proprietary advantage requiring capitalization.

Interpretation and reasoning: The Assessing Officer treated the payments as capital expenditure on the ground that registration added to the value of the trademark and conferred an enduring benefit. The appellate authority considered the assessee's explanation that the expenditures were incurred to meet foreign regulatory requirements, to protect against infringement claims and to avoid future costs or losses, and noted consistent treatment in earlier years and Tribunal precedent allowing the amounts as business expenditure. The Tribunal considered the nature and effect of registration (as explained in Finlay Mills) - i.e., registration eases proof of title and provides a procedural advantage but does not necessarily create a distinct capital asset justifying capitalization - and followed the prior Tribunal decisions applying that principle to like facts.

Ratio vs. Obiter: The holding that the specific professional fees and reimbursements for foreign trade mark registration in the facts of this appeal are revenue in nature and deductible as business expenditure is ratio of the Court; the reliance on Finlay Mills as the controlling principle is treated as ratio supporting that conclusion. Any broader commentary on the test of "enduring benefit" as not to be applied in isolation is part of the Court's reasoning and functions as guiding ratio for analogous assessments; ancillary observations about regulatory context and factual parallels with earlier years are incidental but operative.

Conclusions: The Court upheld the appellate authority's direction to allow the professional fees and reimbursements aggregating Rs. 1,66,327 as business expenditure and to withdraw depreciation claimed on that amount; ground No. 1 is rejected.

Issue 2 - Availability of weighted deduction under section 35(2AB)(1) for clinical trials conducted outside approved in-house R&D facilities

Legal framework: Section 35(2AB)(1) grants a weighted deduction (one and a half times) to a company engaged in specified businesses for "expenditure on scientific research on in-house research and development facility as approved by the prescribed authority." An Explanation defines "expenditure on scientific research" for drugs and pharmaceuticals to include expenditure on clinical drug trials, obtaining regulatory approvals and filing patent applications.

Precedent treatment: The Tribunal in an earlier assessment year (same assessee) considered the identical point and disallowed the weighted (50%) part where the approving authority's certificate explicitly stated that the expenditure related to clinical trials outside the approved facilities. That earlier ITAT decision was applied by the revenue in the present appeal.

Interpretation and reasoning: The Tribunal and the Court analysed the statutory language and concluded that the condition precedent for weighted deduction is that expenditure must be incurred "on in-house research and development facility as approved by the prescribed authority." The Explanation expands the meaning of "expenditure on scientific research" to include clinical trials, but it does not alter or remove the explicit requirement in the main provision that the expenditure be on approved in-house facilities. Reading the Explanation in isolation to permit weighted deduction for outside trials would be inconsistent with the textual structure and legislative intent; if the legislature intended to permit weighted deduction regardless of in-house requirement it would have removed or amended the "in-house" qualification rather than merely adding the Explanation. The approving authority's Form clearly stated the clinical trials were "outside the approved facilities," and no other condition required for the weighted deduction was shown to be unmet apart from the in-house requirement.

Ratio vs. Obiter: The holding that weighted deduction under section 35(2AB)(1) is not available for clinical trial expenditure incurred outside approved in-house R&D facilities is the operative ratio. The explanation that the Explanation to the section cannot be read to override the in-house requirement is core ratio; references to legislative speech and intent are supportive but ancillary.

Conclusions: The Court upheld the Assessing Officer's disallowance of the 50% weighted portion for clinical trials undertaken outside approved in-house facilities and reversed the CIT(A)'s allowance of the weighted part; accordingly the weighted deduction is not allowable in respect of such outside clinical trial expenditure and ground No. 2 is allowed in favor of Revenue to that extent.

---